You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCarvedilol
Accession NumberDB01136  (APRD00091)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-1 adrenergic receptors.

Structure
Thumb
Synonyms
SynonymLanguageCode
(+-)-1-(Carbazol-4-yloxy)-3-((2-(O-methoxyphenoxy)ethyl)amino)-2-propanolNot AvailableNot Available
CarvedilolNot AvailableNot Available
CarvedilolumLatinINN
SKF 105517Not AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Coreg CRcapsule, extended release10 mgoralGlaxo Smith Kline Llc2007-02-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coreg CRcapsule, extended release20 mgoralGlaxo Smith Kline Llc2007-02-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coreg CRcapsule, extended release40 mgoralGlaxo Smith Kline Llc2007-02-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coreg CRcapsule, extended release80 mgoralGlaxo Smith Kline Llc2007-02-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coregtablet, film coated3.125 mgoralGlaxo Smith Kline Llc1997-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coregtablet, film coated6.25 mgoralGlaxo Smith Kline Llc1997-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coregtablet, film coated12.5 mgoralGlaxo Smith Kline Llc1997-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coregtablet, film coated25 mgoralGlaxo Smith Kline Llc1997-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coregtablet, film coated3.125 mgoralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coregtablet, film coated25 mgoralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coregtablet, film coated12.5 mgoralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coregtablet, film coated25 mgoralPhysicians Total Care, Inc.2003-06-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coregtablet, film coated12.5 mgoralPhysicians Total Care, Inc.2002-05-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coregtablet, film coated3.125 mgoralPhysicians Total Care, Inc.2000-11-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coregtablet, film coated6.25 mgoralPhysicians Total Care, Inc.2000-11-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coreg CRcapsule, extended release10 mgoralCarilion Materials Management2007-02-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coreg CRcapsule, extended release20 mgoralCarilion Materials Management2007-02-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coreg CRcapsule, extended release40 mgoralCarilion Materials Management2007-02-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Coreg CRcapsule, extended release80 mgoralCarilion Materials Management2007-02-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Carvediloltablet, film coated3.125 mgoralTeva Pharmaceuticals USA Inc2007-09-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralTeva Pharmaceuticals USA Inc2007-09-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralTeva Pharmaceuticals USA Inc2007-09-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralTeva Pharmaceuticals USA Inc2007-09-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralMylan Pharmaceuticals Inc.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralMylan Pharmaceuticals Inc.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralMylan Pharmaceuticals Inc.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralMylan Pharmaceuticals Inc.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-09-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralSandoz Inc2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralSandoz Inc2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralSandoz Inc2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralSandoz Inc2007-09-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet12.5 mgoralMajor Pharmaceuticals2010-06-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet25 mgoralMajor Pharmaceuticals2010-06-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet3.125 mgoralMajor Pharmaceuticals2010-06-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet6.25 mgoralMajor Pharmaceuticals2010-06-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralMajor Pharmaceuticals2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralMajor Pharmaceuticals2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralMajor Pharmaceuticals2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralMajor Pharmaceuticals2007-09-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralAurolife Pharma LLC2009-03-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralAurolife Pharma LLC2009-03-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralAurolife Pharma LLC2009-03-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralAurolife Pharma LLC2009-03-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralREMEDYREPACK INC.2013-03-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralREMEDYREPACK INC.2013-03-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralAidarex Pharmaceuticals LLC2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralAidarex Pharmaceuticals LLC2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralAidarex Pharmaceuticals LLC2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralAidarex Pharmaceuticals LLC2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralLake Erie Medical DBA Quality Care Products LLC2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralLake Erie Medical DBA Quality Care Products LLC2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralLake Erie Medical DBA Quality Care Products LLC2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralLake Erie Medical DBA Quality Care Products LLC2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralLake Erie Medical DBA Quality Care Products LLC2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralRebel Distributors Corp2009-03-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralAv Kare, Inc.2014-01-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralAv Kare, Inc.2014-01-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralAv Kare, Inc.2014-01-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralAv Kare, Inc.2014-01-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralPd Rx Pharmaceuticals, Inc.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralPd Rx Pharmaceuticals, Inc.2009-03-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralPd Rx Pharmaceuticals, Inc.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralAphena Pharma Solutions Tennessee, Llc2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralAphena Pharma Solutions Tennessee, Llc2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralAphena Pharma Solutions Tennessee, Llc2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralAphena Pharma Solutions Tennessee, Llc2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralAphena Pharma Solutions Tennessee, Llc2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralAphena Pharma Solutions Tennessee, Llc2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralAphena Pharma Solutions Tennessee, Llc2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralAphena Pharma Solutions Tennessee, Llc2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralSolco Healthcare US LLC2010-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralSolco Healthcare US LLC2010-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralSolco Healthcare US LLC2010-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralSolco Healthcare US LLC2010-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet3.125 mgoralREMEDYREPACK INC.2011-08-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralREMEDYREPACK INC.2013-04-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralREMEDYREPACK INC.2013-04-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralREMEDYREPACK INC.2013-04-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralREMEDYREPACK INC.2013-03-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralREMEDYREPACK INC.2013-03-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralREMEDYREPACK INC.2013-05-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet12.5 mgoralREMEDYREPACK INC.2012-01-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralREMEDYREPACK INC.2013-05-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralREMEDYREPACK INC.2013-03-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralREMEDYREPACK INC.2013-04-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralUnit Dose Services2009-03-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralUnit Dose Services2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralUnit Dose Services2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralUnit Dose Services2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralMylan Institutional Inc.2012-12-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralMylan Institutional Inc.2012-12-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralMylan Institutional Inc.2012-12-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralMylan Institutional Inc.2012-12-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mg/301oralNorthwind Pharmaceuticals2014-05-16Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralREMEDYREPACK INC.2013-03-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralREMEDYREPACK INC.2013-03-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralREMEDYREPACK INC.2013-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralREMEDYREPACK INC.2013-02-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralREMEDYREPACK INC.2013-03-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralREMEDYREPACK INC.2013-12-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralREMEDYREPACK INC.2013-05-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralREMEDYREPACK INC.2013-07-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralREMEDYREPACK INC.2013-12-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralREMEDYREPACK INC.2014-02-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralREMEDYREPACK INC.2013-05-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralREMEDYREPACK INC.2013-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralREMEDYREPACK INC.2013-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralREMEDYREPACK INC.2013-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralREMEDYREPACK INC.2013-05-16Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralREMEDYREPACK INC.2013-05-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralREMEDYREPACK INC.2013-05-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralREMEDYREPACK INC.2014-03-19Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralGen Source Rx2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralGen Source Rx2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralGen Source Rx2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralGen Source Rx2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet12.5 mgoralH.J. Harkins Company, Inc.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralH.J. Harkins Company, Inc.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet6.25 mgoralState of Florida DOH Central Pharmacy2009-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet12.5 mgoralState of Florida DOH Central Pharmacy2009-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralState of Florida DOH Central Pharmacy2009-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet25 mgoralState of Florida DOH Central Pharmacy2009-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet3.125 mgoralState of Florida DOH Central Pharmacy2009-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralState of Florida DOH Central Pharmacy2013-01-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralState of Florida DOH Central Pharmacy2013-01-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralState of Florida DOH Central Pharmacy2013-01-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralState of Florida DOH Central Pharmacy2013-01-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralState of Florida DOH Central Pharmacy2013-01-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralState of Florida DOH Central Pharmacy2014-11-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralPhysicians Total Care, Inc.2007-11-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralPhysicians Total Care, Inc.2007-09-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralPhysicians Total Care, Inc.2009-08-12Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralPhysicians Total Care, Inc.2007-09-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralDr. Reddy's Laboratories Limited2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralDr. Reddy's Laboratories Limited2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralDr. Reddy's Laboratories Limited2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralDr. Reddy's Laboratories Limited2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet25 mgoralCardinal Health2010-06-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralCardinal Health2010-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralCardinal Health2010-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralCardinal Health2010-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralCardinal Health2010-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralCardinal Health2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralCardinal Health2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralCardinal Health2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralCardinal Health2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralCardinal Health2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralCardinal Health2008-07-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralCardinal Health2011-02-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralCardinal Health2011-02-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralCardinal Health2011-02-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralCardinal Health2011-02-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralCardinal Health2008-07-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralCardinal Health2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralCardinal Health2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralCardinal Health2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralCaraco Pharmaceutical Laboratories, Ltd.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralCaraco Pharmaceutical Laboratories, Ltd.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralCaraco Pharmaceutical Laboratories, Ltd.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralCaraco Pharmaceutical Laboratories, Ltd.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralClinical Solutions Wholesale2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralClinical Solutions Wholesale2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralClinical Solutions Wholesale2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralClinical Solutions Wholesale2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralHikma Pharmaceutical2007-10-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralHikma Pharmaceutical2007-10-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralHikma Pharmaceutical2007-10-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralHikma Pharmaceutical2007-10-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralApotex Corp.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralApotex Corp.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralApotex Corp.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralApotex Corp.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralSt Marys Medical Park Pharmacy2013-04-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralSt Marys Medical Park Pharmacy2013-04-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralSt Marys Medical Park Pharmacy2013-04-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralSt Marys Medical Park Pharmacy2013-04-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralDIRECT RX2014-01-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralProficient Rx LP2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralbryant ranch prepack2009-03-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralbryant ranch prepack2009-03-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralbryant ranch prepack2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralbryant ranch prepack2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralCadila Healthcare Limited2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralCadila Healthcare Limited2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralCadila Healthcare Limited2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralCadila Healthcare Limited2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralAurobindo Pharma Limited2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralAurobindo Pharma Limited2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralAurobindo Pharma Limited2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralAurobindo Pharma Limited2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralMed Vantx, Inc.2011-09-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralMed Vantx, Inc.2007-09-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet12.5 mgoralRed Pharm Drug Inc.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralBlue Point Laboratories2014-04-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralBlue Point Laboratories2014-04-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralBlue Point Laboratories2014-04-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralBlue Point Laboratories2014-04-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralAmerican Health Packaging2008-07-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralAmerican Health Packaging2008-07-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralAmerican Health Packaging2008-07-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralAmerican Health Packaging2008-07-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralAmerican Health Packaging2014-12-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralAmerican Health Packaging2014-12-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralAmerican Health Packaging2014-12-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralAmerican Health Packaging2014-12-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralZydus Pharmaceuticals (USA) Inc.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralZydus Pharmaceuticals (USA) Inc.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralZydus Pharmaceuticals (USA) Inc.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralZydus Pharmaceuticals (USA) Inc.2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralGlenmark Generics Inc., USA2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralGlenmark Generics Inc., USA2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralGlenmark Generics Inc., USA2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralGlenmark Generics Inc., USA2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralLegacy Pharmaceutical Packaging2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralLegacy Pharmaceutical Packaging2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralLegacy Pharmaceutical Packaging2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralPreferred Pharmaceuticals, Inc2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralPreferred Pharmaceuticals, Inc2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralPreferred Pharmaceuticals, Inc2007-09-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralPreferred Pharmaceuticals,Inc.2014-12-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralPreferred Pharmaceuticals, Inc.2013-03-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralPreferred Pharmaceuticals, Inc.2012-10-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralPreferred Pharmaceuticals,Inc.2012-06-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated3.125 mgoralMc Kesson Contract Packaging2011-09-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated6.25 mgoralMc Kesson Contract Packaging2011-09-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated12.5 mgoralMc Kesson Contract Packaging2011-09-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet, film coated25 mgoralMc Kesson Contract Packaging2011-09-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carvediloltablet3.125 mgoralSivem Pharmaceuticals UlcNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carvediloltablet6.25 mgoralSivem Pharmaceuticals UlcNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carvediloltablet12.5 mgoralSivem Pharmaceuticals UlcNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carvediloltablet25 mgoralSivem Pharmaceuticals UlcNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carvediloltablet3.125 mgoralPro Doc LimiteeNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carvediloltablet6.25 mgoralPro Doc LimiteeNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carvediloltablet12.5 mgoralPro Doc LimiteeNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carvediloltablet25.0 mgoralPro Doc LimiteeNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carvediloltablet3.125 mgoralSanis Health IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carvediloltablet6.25 mgoralSanis Health IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carvediloltablet12.5 mgoralSanis Health IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Carvediloltablet25 mgoralSanis Health IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Over the Counter ProductsNot Available
International Brands
NameCompany
COREGCRNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
CAS number72956-09-3
WeightAverage: 406.4742
Monoisotopic: 406.18925733
Chemical FormulaC24H26N2O4
InChI KeyOGHNVEJMJSYVRP-UHFFFAOYSA-N
InChI
InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
IUPAC Name
1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
SMILES
COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as carbazoles. These are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassCarbazoles
Direct ParentCarbazoles
Alternative Parents
Substituents
  • Carbazole
  • Indole
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Pyrrole
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Azacycle
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of mild or moderate (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin.
PharmacodynamicsCarvedilol is a nonselective beta-adrenergic blocking agent with alpha1-blocking activity and is indicated for the treatment of hypertension and mild or moderate (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin. Carvedilol is a racemic mixture in which nonselective b-adrenoreceptor blocking activity is present in the S(-) enantiomer and a-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol has no intrinsic sympathomimetic activity. The effect of carvedilol's b-adrenoreceptor blocking activity has been demonstrated in animal and human studies showing that carvedilol (1) reduces cardiac output in normal subjects; (2) reduces exercise-and/or isoproterenol-induced tachycardia and (3) reduces reflex orthostatic tachycardia.
Mechanism of actionCarvedilol is a racemic mixture in which nonselective beta-adrenoreceptor blocking activity is present in the S(-) enantiomer and alpha-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol's beta-adrenergic receptor blocking ability decreases the heart rate, myocardial contractility, and myocardial oxygen demand. Carvedilol also decreases systemic vascular resistance via its alpha adrenergic receptor blocking properties. Carvedilol and its metabolite BM-910228 (a less potent beta blocker, but more potent antioxidant) have been shown to restore the inotropic responsiveness to Ca2+ in OH- free radical-treated myocardium. Carvedilol and its metabolites also prevent OH- radical-induced decrease in sarcoplasmic reticulum Ca2+-ATPase activity. Therefore, carvedilol and its metabolites may be beneficial in chronic heart failure by preventing free radical damage.
AbsorptionCarvedilol is rapidly and extensively absorbed following oral administration, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
Volume of distribution
  • 115 L
Protein binding98%
Metabolism

Hepatic. Carvedilol is metabolized primarily by aromatic ring oxidation and glucuronidation. The oxidative metabolites are further metabolized by conjugation via glucuronidation and sulfation. Demethylation and hydroxylation at the phenol ring produce three active metabolites with b-receptor blocking activity. The 4'-hydroxyphenyl metabolite is approximately 13 times more potent than carvedilol for b-blockade.

SubstrateEnzymesProduct
Carvedilol
8-HydroxycarvedilolDetails
Carvedilol
4'-HydroxycarvedilolDetails
Carvedilol
5'-HydroxycarvedilolDetails
Carvedilol
O-DesmethylcarvedilolDetails
Carvedilol
1-HydroxycarvedilolDetails
Carvedilol
Not Available
4'-hydroxyphenyl CarvedilolDetails
Route of eliminationCarvedilol is extensively metabolized. Less than 2% of the dose was excreted unchanged in the urine. Carvedilol is metabolized primarily by aromatic ring oxidation and glucuronidation. The oxidative metabolites are further metabolized by conjugation via glucuronidation and sulfation. The metabolites of carvedilol are excreted primarily via the bile into the feces.
Half life7-10 hours
Clearance
  • 500-700 mL/min
ToxicityNot expected to be toxic following ingestion.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Beta-1 adrenergic receptor
Gene symbol: ADRB1
UniProt: P08588
rs1801253 Not AvailableC AlleleImproved response to blood pressure medication12844134
Beta-1 adrenergic receptor
Gene symbol: ADRB1
UniProt: P08588
rs1801252 Not AvailableA AlleleImproved response to blood pressure medication12844134
Beta-1 adrenergic receptor
Gene symbol: ADRB1
UniProt: P08588
rs1801253 Not AvailableG > CBetter response to drug therapy22192668
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9706
Blood Brain Barrier-0.6814
Caco-2 permeable-0.6308
P-glycoprotein substrateSubstrate0.8552
P-glycoprotein inhibitor INon-inhibitor0.8729
P-glycoprotein inhibitor IINon-inhibitor0.6521
Renal organic cation transporterNon-inhibitor0.5405
CYP450 2C9 substrateNon-substrate0.7517
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5408
CYP450 1A2 substrateInhibitor0.524
CYP450 2C9 substrateNon-inhibitor0.8496
CYP450 2D6 substrateNon-inhibitor0.7274
CYP450 2C19 substrateNon-inhibitor0.5676
CYP450 3A4 substrateNon-inhibitor0.6352
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6048
Ames testNon AMES toxic0.8261
CarcinogenicityNon-carcinogens0.9692
BiodegradationNot ready biodegradable0.963
Rat acute toxicity2.4566 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5725
hERG inhibition (predictor II)Inhibitor0.8889
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseoral10 mg
Capsule, extended releaseoral20 mg
Capsule, extended releaseoral40 mg
Capsule, extended releaseoral80 mg
Tabletoral12.5 mg
Tabletoral25 mg
Tabletoral25.0 mg
Tabletoral3.125 mg
Tabletoral6.25 mg
Tablet, film coatedoral12.5 mg
Tablet, film coatedoral12.5 mg/301
Tablet, film coatedoral25 mg
Tablet, film coatedoral3.125 mg
Tablet, film coatedoral6.25 mg
Prices
Unit descriptionCostUnit
Coreg CR 10 mg 24 Hour Capsule4.77USD capsule
Coreg CR 20 mg 24 Hour Capsule4.77USD capsule
Coreg CR 40 mg 24 Hour Capsule4.77USD capsule
Coreg CR 80 mg 24 Hour Capsule4.77USD capsule
Coreg cr 10 mg capsule4.59USD capsule
Coreg cr 20 mg capsule4.59USD capsule
Coreg cr 40 mg capsule4.59USD capsule
Coreg cr 80 mg capsule4.59USD capsule
Coreg 12.5 mg tablet2.54USD tablet
Coreg 25 mg tablet2.54USD tablet
Coreg 3.125 mg tablet2.54USD tablet
Coreg 6.25 mg tablet2.54USD tablet
Carvedilol 12.5 mg tablet2.18USD tablet
Carvedilol 25 mg tablet2.18USD tablet
Carvedilol 3.125 mg tablet2.18USD tablet
Carvedilol 6.25 mg tablet2.18USD tablet
Apo-Carvedilol 12.5 mg Tablet0.84USD tablet
Apo-Carvedilol 25 mg Tablet0.84USD tablet
Apo-Carvedilol 3.125 mg Tablet0.84USD tablet
Apo-Carvedilol 6.25 mg Tablet0.84USD tablet
Phl-Carvedilol 12.5 mg Tablet0.79USD tablet
Phl-Carvedilol 3.125 mg Tablet0.79USD tablet
Phl-Carvedilol 6.25 mg Tablet0.79USD tablet
Pms-Carvedilol 12.5 mg Tablet0.79USD tablet
Pms-Carvedilol 25 mg Tablet0.79USD tablet
Pms-Carvedilol 3.125 mg Tablet0.79USD tablet
Pms-Carvedilol 6.25 mg Tablet0.79USD tablet
Ran-Carvedilol 12.5 mg Tablet0.79USD tablet
Ran-Carvedilol 25 mg Tablet0.79USD tablet
Ran-Carvedilol 3.125 mg Tablet0.79USD tablet
Ran-Carvedilol 6.25 mg Tablet0.79USD tablet
Ratio-Carvedilol 12.5 mg Tablet0.79USD tablet
Ratio-Carvedilol 25 mg Tablet0.79USD tablet
Ratio-Carvedilol 3.125 mg Tablet0.79USD tablet
Ratio-Carvedilol 6.25 mg Tablet0.79USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States72681562003-12-272023-12-27
United StatesRE400001995-06-072015-06-07
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point114.5 °CPhysProp
water solubilityPractically insoluble (0.583 mg/L)Not Available
logP4.19AVDEEF,A (1997)
Predicted Properties
PropertyValueSource
Water Solubility0.00444 mg/mLALOGPS
logP3.05ALOGPS
logP3.42ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)14.03ChemAxon
pKa (Strongest Basic)8.74ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area75.74 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity115.64 m3·mol-1ChemAxon
Polarizability45.03 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Ilan Kor, “Crystalline solids of carvedilol and processes for their preparation.” U.S. Patent US20030166702, issued September 04, 2003.

US20030166702
General Reference
  1. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002 Oct 22;106(17):2194-9. Pubmed
  2. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651-8. Pubmed
  3. Vanderhoff BT, Ruppel HM, Amsterdam PB: Carvedilol: the new role of beta blockers in congestive heart failure. Am Fam Physician. 1998 Nov 1;58(7):1627-34, 1641-2. Pubmed
External Links
ATC CodesC07AG02
AHFS Codes
  • 24:04.00
  • 24:24.00
PDB EntriesNot Available
FDA labelDownload (1.25 MB)
MSDSDownload (32.9 KB)
Interactions
Drug Interactions
Drug
AcetylcholineBeta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.
AfatinibP-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.
AmifostineAntihypertensives may enhance the hypotensive effect of Amifostine.
AmiodaroneCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
BosutinibP-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.
Brentuximab vedotinP-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.
BretyliumMay enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.
BupivacaineBeta-Blockers may increase the serum concentration of Bupivacaine.
ButabarbitalMay decrease the serum concentration of Beta-Blockers.
ButethalMay decrease the serum concentration of Beta-Blockers.
CapecitabineCYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
CarbacholBeta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.
CimetidineCimetidine may increase the serum concentration of Carvedilol.
ColchicineP-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.
Dabigatran etexilateP-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.
DarunavirMay increase the serum concentration of CYP2D6 Substrates.
DiazoxideMay enhance the hypotensive effect of Antihypertensives.
DigoxinDigoxin may enhance the bradycardic effect of Carvedilol. Carvedilol may increase the serum concentration of Digoxin.
DipyridamoleMay enhance the bradycardic effect of Beta-Blockers.
DisopyramideMay enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.
DronedaroneMay enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6.
DuloxetineHypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.
EtravirineCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
EverolimusP-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.
FingolimodBeta-Blockers may enhance the bradycardic effect of Fingolimod.
FloctafenineMay enhance the adverse/toxic effect of Beta-Blockers.
FloxuridineCYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
FluconazoleCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
FluvastatinCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
GemfibrozilCYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
HeptabarbitalMay decrease the serum concentration of Beta-Blockers.
HexobarbitalMay decrease the serum concentration of Beta-Blockers.
IrbesartanCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
LacosamideBradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.
LedipasvirP-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.
LeflunomideCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
LosartanCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
MepivacaineBeta-Blockers may increase the serum concentration of Mepivacaine.
MethacholineBeta-Blockers may enhance the adverse/toxic effect of Methacholine.
MethohexitalMay decrease the serum concentration of Beta-Blockers.
MethylphenidateMay diminish the antihypertensive effect of Antihypertensives.
MidodrineBeta-Blockers may enhance the bradycardic effect of Midodrine.
NicardipineMay enhance the hypotensive effect of Carvedilol. NiCARdipine may precipitate signs of heart failure in susceptible patients on Carvedilol NiCARdipine may increase the serum concentration of Carvedilol.
ObinutuzumabAntihypertensives may enhance the hypotensive effect of Obinutuzumab.
OmeprazoleCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
PanobinostatMay increase the serum concentration of CYP2D6 Substrates.
PazopanibP-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.
Peginterferon alfa-2bMay decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.
PentobarbitalMay decrease the serum concentration of Beta-Blockers.
PentoxifyllineMay enhance the hypotensive effect of Antihypertensives.
PrimidoneMay decrease the serum concentration of Beta-Blockers.
PropafenoneMay increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.
prucaloprideP-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.
PyrimethamineCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
QuinineCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
RegorafenibMay enhance the bradycardic effect of Beta-Blockers.
ReserpineMay enhance the hypotensive effect of Beta-Blockers.
RifaximinP-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.
RisperidoneHypotensive Agents may enhance the hypotensive effect of RisperiDONE.
RituximabAntihypertensives may enhance the hypotensive effect of RiTUXimab.
RivaroxabanP-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.
RivastigmineMay enhance the bradycardic effect of Beta-Blockers.
RuxolitinibMay enhance the bradycardic effect of Bradycardia-Causing Agents.
SecobarbitalMay decrease the serum concentration of Beta-Blockers.
SilodosinP-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.
SorafenibCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
SulfadiazineCYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
SulfamethoxazoleCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
SulfisoxazoleCYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
TadalafilMay enhance the antihypertensive effect of Antihypertensives.
TicagrelorCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
TofacitinibMay enhance the bradycardic effect of Bradycardia-Causing Agents.
TolbutamideCYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
TopotecanP-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.
TrimethoprimCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
VardenafilMay enhance the antihypertensive effect of Antihypertensives.
VoriconazoleCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
YohimbineMay diminish the antihypertensive effect of Antihypertensives.
ZafirlukastCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
Food Interactions
  • Take with food, food slows the absorption rate and reduces the incidence of adverse effects (extent of absorption is not affected).

Targets

1. Beta-1 adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Beta-1 adrenergic receptor P08588 Details

References:

  1. Nichols AJ, Gellai M, Ruffolo RR Jr: Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol. 1991;5(1):25-38. Pubmed
  2. Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR Jr: In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology. 1989;39(5):327-36. Pubmed
  3. Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR Jr: The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors. Chirality. 1989;1(4):265-70. Pubmed
  4. de Mey C, Breithaupt K, Schloos J, Neugebauer G, Palm D, Belz GG: Dose-effect and pharmacokinetic-pharmacodynamic relationships of the beta 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans. Clin Pharmacol Ther. 1994 Mar;55(3):329-37. Pubmed

2. Alpha-1A adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1A adrenergic receptor P35348 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

3. NADH dehydrogenase [ubiquinone] 1 subunit C2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
NADH dehydrogenase [ubiquinone] 1 subunit C2 O95298 Details

References:

  1. Oliveira PJ, Santos DJ, Moreno AJ: Carvedilol inhibits the exogenous NADH dehydrogenase in rat heart mitochondria. Arch Biochem Biophys. 2000 Feb 15;374(2):279-85. Pubmed

4. Beta-2 adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Beta-2 adrenergic receptor P07550 Details

References:

  1. Irodova NL, Krasnikova TL, Masenko VP, Kochetov AG, Chazova IE: [Carvedilol in treating primary pulmonary hypertension patients: effect on severity of cardiac failure, degree of pulmonary hypertension, concentration of catecholamines in blood plasma and dependence of cyclic AMP synthesis in lymphocytes on beta-adrenergic receptors] Ter Arkh. 2002;74(8):30-4. Pubmed
  2. Maebara C, Ohtani H, Sugahara H, Mine K, Kubo C, Sawada Y: Nightmares and panic disorder associated with carvedilol overdose. Ann Pharmacother. 2002 Nov;36(11):1736-40. Pubmed
  3. Okajima K, Harada N, Uchiba M, Isobe H: Activation of capsaicin-sensitive sensory neurons by carvedilol, a nonselective beta-blocker, in spontaneous hypertensive rats. J Pharmacol Exp Ther. 2004 May;309(2):684-91. Epub 2004 Feb 5. Pubmed
  4. Nichols AJ, Gellai M, Ruffolo RR Jr: Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol. 1991;5(1):25-38. Pubmed

5. Vascular endothelial growth factor A

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: other

Components

Name UniProt ID Details
Vascular endothelial growth factor A P15692 Details

References:

  1. de Boer RA, Siebelink HJ, Tio RA, Boomsma F, van Veldhuisen DJ: Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure. Eur J Heart Fail. 2001 Jun;3(3):331-3. Pubmed
  2. Saijonmaa O, Nyman T, Fyhrquist F: Carvedilol inhibits basal and stimulated ACE production in human endothelial cells. J Cardiovasc Pharmacol. 2004 May;43(5):616-21. Pubmed
  3. Shyu KG, Lu MJ, Chang H, Sun HY, Wang BW, Kuan P: Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure. J Card Fail. 2005 Mar;11(2):152-9. Pubmed
  4. Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H: Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci. 2005;12(2):409-20. Pubmed

6. Natriuretic peptides B

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: other

Components

Name UniProt ID Details
Natriuretic peptides B P16860 Details

References:

  1. Ohta Y, Watanabe K, Nakazawa M, Yamamoto T, Ma M, Fuse K, Ito M, Hirono S, Tanabe T, Hanawa H, Kato K, Kodama M, Aizawa Y: Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J Cardiovasc Pharmacol. 2000;36 Suppl 2:S19-23. Pubmed
  2. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, Frampton C, Yandle TG: Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol. 2001 Jun 1;37(7):1781-7. Pubmed
  3. Konishi H, Nishio S, Tsutamoto T, Minouchi T, Yamaji A: Serum carvedilol concentration and its relation to change in plasma brain natriuretic peptide level in the treatment of heart failure: a preliminary study. Int J Clin Pharmacol Ther. 2003 Dec;41(12):578-86. Pubmed
  4. Takeda Y, Fukutomi T, Suzuki S, Yamamoto K, Ogata M, Kondo H, Sugiura M, Shigeyama J, Itoh M: Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol. 2004 Aug 15;94(4):448-53. Pubmed
  5. Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP, Hanna RD, Backes RJ, Mookadam F, Heublein D, Bailey KR, Burnett JC: Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J. 2005 Mar;149(3):541-7. Pubmed

7. Gap junction alpha-1 protein

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: other

Components

Name UniProt ID Details
Gap junction alpha-1 protein P17302 Details

References:

  1. Yeh HI, Lee PY, Su CH, Tian TY, Ko YS, Tsai CH: Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment. Am J Hypertens. 2006 Feb;19(2):129-35. Pubmed
  2. Fan SY, Ke YN, Zeng YJ, Wang Y, Cheng WL, Yang JR: [Effects and the mechanism of carvedilol on gap junctional intercellular communication in rat myocardium] Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Dec;33(12):1141-5. Pubmed

8. Potassium voltage-gated channel subfamily H member 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Potassium voltage-gated channel subfamily H member 2 Q12809 Details

References:

  1. Karle CA, Kreye VA, Thomas D, Rockl K, Kathofer S, Zhang W, Kiehn J: Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res. 2001 Feb 1;49(2):361-70. Pubmed
  2. Kawakami K, Nagatomo T, Abe H, Kikuchi K, Takemasa H, Anson BD, Delisle BP, January CT, Nakashima Y: Comparison of HERG channel blocking effects of various beta-blockers— implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. Pubmed

9. Vascular cell adhesion protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Vascular cell adhesion protein 1 P19320 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Chen JW, Lin FY, Chen YH, Wu TC, Chen YL, Lin SJ: Carvedilol inhibits tumor necrosis factor-alpha-induced endothelial transcription factor activation, adhesion molecule expression, and adhesiveness to human mononuclear cells. Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2075-81. Epub 2004 Sep 16. Pubmed

10. Alpha-1D adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1D adrenergic receptor P25100 Details

References:

  1. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A: Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. Pubmed
  2. Van Tassell BW, Rondina MT, Huggins F, Gilbert EM, Munger MA: Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction. Am Heart J. 2008 Aug;156(2):315-21. doi: 10.1016/j.ahj.2008.04.004. Epub 2008 Jun 20. Pubmed

11. Alpha-1B adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1B adrenergic receptor P35368 Details

References:

  1. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A: Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. Pubmed

12. Alpha-2C adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-2C adrenergic receptor P18825 Details

References:

  1. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A: Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. Pubmed

13. Alpha-2B adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-2B adrenergic receptor P18089 Details

References:

  1. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A: Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. Pubmed

14. Alpha-2A adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-2A adrenergic receptor P08913 Details

References:

  1. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A: Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. Pubmed

15. E-selectin

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
E-selectin P16581 Details

References:

  1. Chen JW, Lin FY, Chen YH, Wu TC, Chen YL, Lin SJ: Carvedilol inhibits tumor necrosis factor-alpha-induced endothelial transcription factor activation, adhesion molecule expression, and adhesiveness to human mononuclear cells. Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2075-81. Epub 2004 Sep 16. Pubmed

16. Hypoxia-inducible factor 1-alpha

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: modulator

Components

Name UniProt ID Details
Hypoxia-inducible factor 1-alpha Q16665 Details

References:

  1. Shyu KG, Lu MJ, Chang H, Sun HY, Wang BW, Kuan P: Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure. J Card Fail. 2005 Mar;11(2):152-9. Pubmed

Enzymes

1. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Xanthine dehydrogenase/oxidase

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Xanthine dehydrogenase/oxidase P47989 Details

References:

  1. Yue TL, McKenna PJ, Gu JL, Cheng HY, Ruffolo RE Jr, Feuerstein GZ: Carvedilol, a new vasodilating beta adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils. Cardiovasc Res. 1994 Mar;28(3):400-6. Pubmed

4. Cytochrome P450 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

6. Cytochrome P450 1A1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 1A1 P04798 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

7. Cytochrome P450 2E1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2E1 P05181 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

8. Prostaglandin G/H synthase 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Prostaglandin G/H synthase 1 P23219 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. Pubmed
  2. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. Pubmed
  3. Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K: Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol. 1999 Dec 1;58(11):1801-6. Pubmed
  4. Neuhoff S, Langguth P, Dressler C, Andersson TB, Regardh CG, Spahn-Langguth H: Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther. 2000 Apr;38(4):168-79. Pubmed
  5. Hokama N, Hobara N, Sakai M, Kameya H, Ohshiro S, Sakanashi M: Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats. J Pharm Pharmacol. 2002 Jun;54(6):821-5. Pubmed
  6. Kakumoto M, Sakaeda T, Takara K, Nakamura T, Kita T, Yagami T, Kobayashi H, Okamura N, Okumura K: Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil. Cancer Sci. 2003 Jan;94(1):81-6. Pubmed
  7. Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:13